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1. Introduction 
The coccidian Toxoplasma gondii (T. gondii) is a ubiquitous, intracellular, protozoan parasite 
that causes toxoplasmosis, a cosmopolitan zoonotic disease. Toxoplasma infections are 
reported in approximately half of the world’s population but most are asymptomatic. T. 
gondii may serve as one factor that can enhance the immunodeficiency found after HIV-1 
infections.  Co-infection with other pathogens in humans infected with HIV-1 may enhance 
the progression of the disease to AIDS (Lin & Bowman, 1992). In concurrence with HIV 
infection, cerebral toxoplasmosis (CT) occurs primarily due to reactivation of latent 
Toxoplasma infection and is one of the most frequent opportunistic infections, particularly in 
patients with full-blown AIDS. CT is the most common clinical presentation of 
toxoplasmosis (Luft & Remington, 1992), and is one of the most frequent causes of focal 
intracerebral lesions that complicates AIDS (Nissapatorn et al, 2004). CT is undoubtedly a 
serious life-threatening disease but it is treatable when there is a timely diagnosis and 
prompt treatment, and there are no other concurrent co-infections. When HIV-infected 
patients develop CT this poses many diagnostic and therapeutic challenges for clinicians 
(Israelski & Remington, 1992), particularly in developing countries where the infrastructure 
is limited but the number of patients infected with HIV is increasing. This chapter focuses 
on the clinico-epidemiological aspects of toxoplasmosis in HIV/AIDS patients at the time of 
transition to treatment with highly active anti-retroviral therapy (HAART). The course of 
toxoplasmosis in HIV/AIDS patients should be able to provide us with a better 
understanding of the clinical scenario and future management of this so-called “enigmatic 
parasite” of the tropics.  
2. Pathogenesis - from source to host defense mechanism 
2.1 Morphology 
T. gondii is a coccidian, that is ubiquitous and an obligate intracellular parasite with a 
complex life cycle and felids are the definitive hosts. There are three infectious stages of T. 
gondii in the environment. Tachyzoites (or endozoites), crescent to oval in shape, are seen in 
an active infection. They can be transmitted through the placenta from mother to fetus, by 
blood transfusion, or by organ transplantation. Tissue cysts, containing thousands of 
bradyzoites, the terminal life cycle stage, are transmitted by eating infected meat or organs, 
and may persist life-long in an intermediate host. In this stage, they are associated with 
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latent infections, but reactivation occurs in persons who lose their immunity. Bradyzoites (or 
cystozoites) are less susceptible to chemotherapy and the presence of this infective stage in 
host tissues is of clinical significance, particularly in immunosuppressed individuals. The 
oocyst stage, is excreted in the cat’s feces, and this most tolerant form of T. gondii, is 
ubiquitous in nature, is highly resistant to disinfectants and environmental influences, as 
well as playing a key role in transmission through the fecal-oral route.  
2.1.1 Life cycle and transmission 
The life cycle of T. gondii was described in 1970, before it was determined that members of 
the family Felidae, including domestic cats, were the definitive hosts and warm-blooded 
animals including most livestock and humans serve as intermediate hosts (Figure 1). In 
contrast to other protozoans, T. gondii is a parasite that can parasitize all mammals. T. gondii 
has a large host range; this parasite can be found throughout the world. T. gondii is a 
common infection in humans; it becomes more important in the field of veterinary and 
medical infectious diseases. T. gondii is a potential organism causing a serious public health 
hazard due to infected meat-producing animals and a severe economic loss to the livestock 
owners. T. gondii can be transmitted (Figure 2) through one of the following routes (Tenter et 
al, 2000; Derouin et al, 2008).  
 
 
Fig. 1. The life cycle of T. gondii. 
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In the definitive hosts, infection with T. gondii occurs following not only ingestion of tissue 
cysts in under-cooked meat but also after ingesting the rapidly-multiplying tachyzoite forms 
or the oocysts shed in feces. The cyst wall of T. gondii is dissolved by the proteolytic 
enzymes of both stomach and small intestine, releasing the slowly-multiplying bradyzoite 
form. The asexual cycle begins after the invasion of T. gondii into the epithelial cells of the 
small intestine. While, the sexual cycle is very specific and occurs only in the gut epithelial 
cells of feline species. The oocyst forms are produced by gamete fusion and are then shed in 
the feces of the definitive hosts. These oocysts are highly infective to other definitive and 
intermediate hosts once they are in contact with a susceptible environment (Frenkel, 1973). 
The oocysts of T. gondii are less infective and pathogenic in the definitive host (cat) as 
compared with intermediate hosts (mice, pigs, humans) (Dubey, 1998). 
In intermediate hosts, T. gondii undergoes two phases of asexual development. The infective 
stages (sporozoites or bradyzoites) transform into tachyzoites following Toxoplasma infection 
of the intestinal epithelial cells. In the first phase, tachyzoites multiply rapidly by repeated 
endodyogeny in an intracellular parasitophorous vacuole in many different types of host 
cells. The second phase develops from the tachyzoites of the last generation and results in 
tissue cysts (Tenter et al, 2000). Within the tissue cyst, bradyzoites multiply slowly by 
endodyogeny. Tissue cysts have a high affinity for neural and muscular tissues and are 
located mainly in the central nervous system (CNS), eye, skeletal and cardiac muscles as 
well as other visceral organs (Dubey et al, 1998). Tissue cysts break down periodically, with 
bradyzoites transforming into tachyzoites that reinvade host cells and again transform to 
bradyzoites within new tissue cysts (Dubey, 1998).  
 
 
Fig. 2. The different routes of T. gondii transmission. 
www.intechopen.com
 Microbes, Viruses and Parasites in AIDS Process 
 
310 
2.1.2 T. gondii antigens, host defense mechanisms and cerebral toxoplasmosis 
In patients with AIDS, tissue cysts rupture and the released bradyzoites may multiply 
locally and spread to other organs. Infected patients may have serious complications or even 
death from symptomatic toxoplasmosis. The pathology of Toxoplasma infection is due to the 
invasion process initiating the lytic cycle that consequently leads to cell and tissue 
destruction. In the host cell cytoplasm, T. gondii induces the formation of a parasitophorous 
vacuole that contains secretions of both parasite and host proteins that normally promote 
phagosome maturation, , and thereby prevent lysosome fusion  (Dubey et al, 1998; 
Carruthers, 2002). Despite this rapid, dynamic and significant process, there are very few 
secretory proteins that have so far been discovered (Zhou et al, 2005). These proteins 
(antigens) are essential components for low-grade stimulation that boosts the immune 
system. These antigens have been shown to stimulate antibody production as well as a T-cell 
response (Carruthers, 2002).  
T. gondii excretory/secretory antigens (ESAs) represent the majority of the circulating 
antigens in host sera of patients with acute toxoplasmosis (Pereira-Chioccola et al, 2009). 
ESAs include the tachyzoite, sporozoite and encysted bradyzoite stages (Tilley et al, 1997). 
The secretions by the bradyzoite cysts maintain a long-lasting immunity to T. gondii 
(Cesbron-Delauw & Capron, 1993). The ESAs released by tachyzoites are highly 
immunogenic (Prigione et al, 2000; Carruthers, 2002) and may induce either antibody 
dependent or cell mediated immunity (Costa-Silva et al, 2008). Anti-ESA antibodies 
develop in high titers when circulating blood tachyzoites are present in AIDS-associated 
CT patients (Meira et al, 2008). Toxoplasma infection results in pathological changes such 
as inflammation and is usually followed by necrosis. This parasitic infection also induces 
strong type 1 polarized innate and adaptive immune responses. It is known that the host 
defense mechanism to infection with T. gondii is mediated by production of pro-
inflammatory cytokines, including IL-12, IFN- and TNF- (Suzuki et al, 1989). The 
important sources of IFN- in response to Toxoplasma infection are CD4-T lymphocytes, 
CD8-T lymphocytes, natural killer cells and T cells responding to IL-12 (Yap et al, 2000). 
These major mechanisms prevent rapid replication of tachyzoites and subsequent 
pathological changes (Denkers, 2003). Of these, T lymphocytes are a crucial source of IFN-
 during the first 2-3 weeks after infection, as demonstrated in antibody-mediated T-cell 
depletion experiments that resulted in reactivation of Toxoplasma infection (Denkers, 
2003). In the chronic phase, the tissue cysts can persist indefinitely in the brain and 
muscle, developing lifelong protective immunity against re-infection (Dubey, 1998; 
Montoya & Liesenfeld, 2004). There are re-infections in some cases because slightly 
different genotypes of T. gondii strains have been found in the same patients (Ferreira et 
al, 2008). In the clinical phase, tissue cysts are periodically ruptured, but the bradyzoites 
released are normally destroyed by the host immune response. At the time when 
asymptomatic individuals become immune deficient, secondary reactivation of 
latent/chronic infection may occur, culminating in the conversion of bradyzoites to the 
active and rapidly replicating tachyzoites, as a result of tissue injury which is often fatal. 
As the cysts have a predilection for neural, muscle tissue and the eye, most cases 
reactivate chorioretinitis or, more frequently, cerebral toxoplasmosis, which is the 
predominant manifestation in patients with AIDS. Apart from these mechanisms, the 
development of cerebral toxoplasmosis has recently been studied and shown to have a 
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significant correlation with the HLA genes (class I and class II) in HIV-infected patients. 
The MHC is one of the most polymorphic genetic systems in humans and controls the 
adaptive immune response by class I (HLA-A, HLA-B, HLA-Cw) and class II (HLA-DRB1, 
HLA-DQB1, HLA-DPB1) against both intra-and extracellular microorganisms as well as it 
being correlated with infection susceptibility or resistance. Class I HLA-B35 antigen was 
associated with retinochoroiditis (Veronese Rodrigues et al, 2004). Class I HLA-B8 and 
class II HLA-DRB1*17 antigens were associated with cerebral toxoplasmosis (Castro 
Figueiredo et al, 2000). The presence of class II HLA-DQB1*0402 and DRB1*08 alleles 
(Habegger de Sorrentino et al, 2005) and the HLA-DR52 haplotype represent risk factors 
to the development of cerebral toxoplasmosis, whereas the HLA-DR53 haplotype was 
associated with resistance to Toxoplasma infection (Pereira-Chioccola et al, 2009).  
Among patients with AIDS, CT is a multifocal process that occurs spontaneously. The use of 
the highly sensitive technique of magnetic resonance imaging (MRI) reveals that >80% of 
patients will have multiple lesions (Ciricillo & Rosenblum, 1990). With this technique, the 
percentages are probably an underestimation of the multifocal pathological process that 
may be occurring as they will be below its resolution. The spontaneous and simultaneous 
development of multifocal brain lesions strongly indicates that although CT arises because 
of reactivation of a latent infection, the multiple areas of the brain that are involved are 
likely a result of the hematogenous spread of the parasite, and involvement of the brain is 
due to the particular proclivity of T. gondii for causing disease in the CNS (Luft & 
Remington, 1992). The latter is likely due to the fact that the brain is an immunologically 
original site rather than an actual site of the organism. This supposition is further supported 
by the observation that patients who relapse after receiving an adequate course of therapy 
often develop new lesions in areas of the brain previously free of infection (Leport et al, 
1989). 
3. Epidemiology - from source to gene 
The high rates of latent Toxoplasma infection (41.9–72%) were reported in South America and 
in approximately half of the studies ( 40%) from the Asian continent. In North America, 
however, the rate of Toxoplasma infection was low. Surprisingly, only 8 of the 50 studies 
were conducted on HIV-infected pregnant women and 2 of those studies, interestingly, 
reported a very high seroprevalence of toxoplasmosis of 53.7% in Thailand and 72% in 
Brazil. Latent toxoplasmosis is still prevalent as an infection that coexists with HIV infection. 
The level of anti-Toxoplasma (IgG) antibodies was, interestingly, unaffected by either 
antiretroviral drugs or therapeutic regimes/prophylaxis used for toxoplasmosis in these 
patients (Machala et al, 2009). Supporting these epidemiological studies, screening for 
Toxoplasma infection should be included in routine investigations in order to monitor 
primary infections even though it is not very common in such patients. It may also prevent 
secondary reactivation of latent infections, especially in HIV-infected patients with limited 
resource settings where the majority are unable to access primary chemoprophylaxis and/or 
antiretroviral therapy. 
How do the plausible risk factors play their roles in association with Toxoplasma infection in 
HIV-infected patients? Age and race/ethnicity, among other demographic characteristics, 
were shown to have a positive interaction with this parasite. A study from the United States 
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demonstrated that Toxoplasma prevalence rates reported in HIV-infected women aged  50 
years were significantly higher compared to those who were younger (Falusi et al, 2002). 
This was dissimilar to a study from Malaysia which reported that HIV-infected patients in 
the younger age group had higher Toxoplasma seroprevalence rates than the older age 
group although it was not statistically significant (Nissapatorn et al, 2001). Based on these 
findings, Toxoplasma infection is acquired irrespective of age, and preventive measures are 
needed to curb the prevalence rate especially in areas where the parasite is highly 
endemic. The study by Falusi and colleagues in 2001 further pointed out that those 
women born outside the U.S. were more likely to have higher rates of latent 
toxoplasmosis although race did not affect Toxoplasma seroprevalence between black and 
white women in that country (Falusi et al, 2002). In a country like Malaysia, a higher rate 
of Toxoplasma infection was more likely to be found among Malays, the predominant 
ethnic group in this region compared to others including Chinese and Indian 
(Nissapatorn et al, 2007). Traditionally, Malays keep cats as pets, which could explain this 
association. Based on these studies, demographic characteristics certainly make significant 
contributions to the epidemiological surveillance of Toxoplasma infection in a given 
population, such as HIV/AIDS patients. 
 
 
Fig. 3. Global status of latent Toxoplasma infection in HIV-infected patients.  
Dark red equals prevalence above 60%, light red equals 40-60%, yellow 20-40%, blue 10-20% 
and green equals prevalence <10%. White equals absence of data. (Courtesy of Dr. 
Rattanasinchaiboon O and Dr Phumkokrux S, Bangkok, Thailand.) 
There are not many studies on how the T-cell response could affect Toxoplasma-seropositive 
patients. It has been recognized that T-helper (CD4) cells, among several types of T-cell 
responses, are involved in Toxoplasma infection by stimulating T-cytotoxic cells which are 
then able to lyse tachyzoites directly and participate in the activation of B-cells which then 
go on to produce antibodies against Toxoplasma (Ho-Yen, 1992.). An earlier study showed 
that there is a greater likelihood of problems with Toxoplasma infection in situations in which 
there is a reduction of T-cell function (Pendry et al, 1990). Supporting this literature, a U.S. 
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study demonstrated a significant association between CD4 counts of 200-499 cells/mm3 and 
Toxoplasma-seropositivity in patients (Falusi et al, 2002). The authors were unable to provide 
an explanation for this association except that patients with low CD4 counts were more 
likely to be foreign born. So far, similar findings have not been reported from previous 
studies (Nissapatorn et al, 2001; Nissapatorn et al, 2002). Looking at other possible risk 
factors such as a history of close contact with cats, consumption of contaminated meat, and 
receiving blood transfusions from Toxoplasma-seropositive patients, there was however no 
significant association found from studies reported earlier (Wallace et al, 1993; Nissapatorn 
et al, 2001; Nissapatorn et al, 2002). This possibly explains that these patients had been 
constantly exposed to Toxoplasma infections (with no definite time frame) before acquiring 
HIV infection. The other reason is that patients acquired Toxoplasma infection from other 
sources such as eating raw vegetables or drinking contaminated water, risk factors that were 
not included in these studies. However, primary behavioral practice such as avoiding close 
contact with cats, consumption of clean and properly cooked foods is necessary and 
advisable for HIV-infected patients regardless of Toxoplasma serostatus. Interestingly, 
patients with Toxoplasma-seropositivity were more likely to develop CT and tended to be 
patients receiving HAART (Nissapatorn et al, 2007). From this observation, primary 
chemoprophylaxis or antiretroviral drugs including HAART (if available) should be 
instituted to these patients after clinical evaluation. 
Apart from the host immune status, the genotype of the infecting parasites may influence 
the course of disease (Lindström et al, 2006). Genetic analyses have shown that the vast 
majority of all T. gondii-strains typed to date fall into one of three clonal lineages, type I, II, 
and III (Howe & Sibley, 1995), which differ in virulence but do not show clear host or 
geographic boundaries (Lindström et al, 2006). Studies from different parts of the world 
have produced similar findings in which the genotyping of the SAG2-locus revealed that the 
type II allele was the most disease-causing strain (reactivation of chronic infections) found in 
immunocompromised individuals (Dardé et al, 1992; Howe and Sibley, 1995; Howe et al, 
1997; Fuentes et al, 2001; Lindström et al, 2006; Ajzenberg et al, 2009). 
This high prevalence of type II strains in human toxoplasmosis may simply reflect the 
source of the strains that led to human infections (Howe et al, 1997). Also, the low level of 
gamma interferon and other factors related to the immune system in these patients might 
increase the possibility of reactivation of the infective forms of the parasite by developing 
bradyzoites and increasing the formation of cysts in the brain (Gross et al, 1997).  During 
this same period, a few studies have reported on uncommon type I strains (Khan et al, 2005), 
type I/III (Genot et al, 2007), and a high rate of genetic polymorphism (Ferreira et al, 2008) 
in T. gondii strains isolated from immunocompromised patients. Despite these differences, 
genotyping studies could serve as an important mile-stone for improving the diagnosis and 
management of human toxoplasmosis, in addition, for the development of novel drugs and 
vaccines. Surprisingly, genotyping studies on T. gondii strains have not been reported from 
HIV-infected patients in the Asian continent even though there are a number of these 
patients, in endemic areas for latent Toxoplasma infections (Subsai et al, 2006; Nissapatorn et 
al, 2007), and cases of clinical toxoplasmosis detected in AIDS patients (Subsai et al, 2006; 
Lian et al, 2007). Future studies are recommended to elucidate the distribution of genotypes 
and to establish any correlations between genotyping of T. gondii strains and human 
toxoplasmosis in Asian HIV patients.  
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Based on these findings, it certainly poses a question as to whether there is an association 
between genotyping of T. gondii strains and human toxoplasmosis. One study interestingly 
indicates that the type of infecting parasitic strain does not predominantly influence the 
pathogenesis of toxoplasmosis in immunocompromised patients and fully support the need 
for specific prophylaxis in patients infected by T. gondii, regardless of the strain genotype 
(Honoré et al, 2000). In addition, other host factors are more involved than parasite factors in 
patients’ resistance or susceptibility to toxoplasmosis in immunocompromised hosts 
(Ajzenberg et al, 2009).  
A total of 50 studies have been reported from different parts of the world including Asia, 
Europe, North America, South America and Africa (Table 1). The varying seroprevalence of 
toxoplasmosis (latent/chronic infection) interestingly showed low to high rates of infection 
being >60% (9 studies), 40-60%, (12 studies), 20-40% (21 studies), 10-20% (3 studies), and 
<10% (5 studies). 
 
Study (Ref) City, Country No. of HIV/AIDS 
patients   
Seroprevalence  
in % 
Asia    
Wongkamchai et al, 1995 Bangkok, Thailand 40  42.5 
Meisheri et al, 1997 Bombay, India 89  67.8 
Yoong and Cheong, 1997 Kuala Lumpur, Malaysia 49  59.0 
Chintana et al, 1998 Bangkok, Thailand 253 (pregnancy) 21.1 
Sukthana et al, 2000 Bangkok, Thailand 190  23.2 
Oh et al, 1999 Seoul, South Korea 173  4.0 
Nissapatorn et al, 2001 Bangkok, Thailand 183  22.4 
Shivaprakash et al, 2001 Pondicherry, India 216  11.5 (IgM) 
Wanachiwanawin et al, 2001  Bangkok, Thailand  838 (pregnancy)  53.7  
Shamilah et al, 2001  Kuala Lumpur, Malaysia  729  31.3  
Nissapatorn et al, 2002  Kuala Lumpur, Malaysia  100  21.0  
Nissapatorn et al, 2003  Kuala Lumpur, Malaysia  406  51.2  
Nissapatorn et al, 2004  Kuala Lumpur, Malaysia  505  44.8  
Hung et al, 2005  Taipei, Taiwan  844  10.2  
Nissapatorn et al, 2005  Kuala Lumpur, Malaysia  162  35.8 and 14.8 
(IgM)  
Naito et al, 2007  Tokyo, Japan  56  5.40  
Nissapatorn et al, 2007  Kuala Lumpur, Malaysia  693  43.85  
Nissapatorn et al, [In print]  Songkhla, Thailand  300  36.3  
Europe     
Holliman, 1990 London, UK  500  26.6 and 1.4 (IgM)  
Sykora et al, 1992  Prague, Czechoslovakia  67  29.8  
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Study (Ref) City, Country No. of HIV/AIDS 
patients   
Seroprevalence  
in % 
Zufferey et al, 1993  Lausanne, Switzerland  715  50.0  
Oksenhendler et al, 1994  Villejuif, France  499  25.4  
Raffi et al, 1997  Nantes cedex, France  186  97  
Bossi et al, 1998  Paris, France  399  97  
Letillois et al, 1995 Grenoble, France  37  64.9  
Reiter-Owona et al, 1998 Bon, Germany 183  33.3 (in 1987) and 
36.6 (in 1995) 
Millogo et al, 2000  Burkina Faso, France  1,828  25.4  
Machala et al, 2009 Prague, Czech Republic  626  33.2  
North America    
Grant et al, 1990  New York, USA  411  32.0  
Israelski et al, 1993  California, USA  1,073  11.0  
Minkoff et al, 1997  Brooklyn, USA  138  20.2  
Ruiz et al, 1997  Rhode Island, USA  169 (pregnancy)  22.0  
Falusi et al, 2002  Chicago, USA  1,975  15.1  
South America     
Wainstein et al, 1993 RS, Brazil 516  65 and 49 (CSF) 
Galván Ramirez et al, 1997 Universidad de 
Guadalajara, Mexico 
92  50.0 and 1.0 (IgM) 
Cruz et al, 2007  RJ, Brazil  767 (pregnancy)  74.0  
Lago et al, 2009 Rio Grande do Sul, Brazil  168 (pregnancy)  72.0  
Africa     
Brindle et al, 1991 Kenya, Nairobi 94  22 
Zumla et al, 1991 Zambia and Uganda 373 (186-Uganda 
and 187-Zambia)  
34 (Ugandan) and 
4 (Zambian) 
Woldemichael et al, 1998 Addis Ababa, Ethiopia 127  74.2 
Maïga et al, 2001 Bamako, Mali  ? 22.6 and 60  
Uneke et al, 2005 Jos, Nigeria 219  38.8 
Lindström et al, 2006 Kampala, Uganda 130  54 
Hari et al, 2007 Johannesburg, South 
Africa 
307  8 
Ouermi et al, 2009 Burkina faso, agadougou  138 (pregnancy)  31.9 and 3.6 (IgM) 
Akanmu et al, 2010 Lagos, Nigeria  380  54 
Sitoe et al, 2010 Maputo, Mozambique  58 (pregnancy) 31.3 
Oshinaike et al, 2010  Lagos, Idi Araba, Nigeria  83  85.5  
Table 1. Summary of studies on seroprevalence of toxoplasmosis in HIV-infected patients. 
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4. Toxoplasmosis - from epidemiology to clinical implication 
4.1 Congenital toxoplasmosis  
Seven of the 50 studies were conducted on HIV-infected pregnant women, 2 reported a high 
seroprevalence, 53.7% in Thailand (Wanachiwanawin et al, 2001) and 74% in Brazil (Cruz et 
al, 2007). Considering these epidemiological studies (Table 1), geographical location, 
environment, socio-economic, clinical and diagnostic methods are among the factors that 
can pin point the differences of Toxoplasma infections between these affected areas. Latent 
toxoplasmosis is still prevalent and coexists with HIV infections. The level of anti-
Toxoplasma (IgG) antibodies does not appear to be affected by antiretroviral drugs or 
therapeutic regimes/prophylaxis used to treat toxoplasmosis in these patients (Machala et 
al, 2009). Given the results of these epidemiological studies, screening for Toxoplasma 
serostatus should be carried out among HIV-infected women in the prenatal period even 
though it is not a common practice. It may also prevent secondary reactivation of latent 
toxoplasmosis during pregnancy, especially among HIV-infected women in limited resource 
settings where the majority of these patients are unable to access primary chemoprophylaxis 
and/or antiretroviral therapy.  
In HIV-infected pregnant women, a secondary reactivation of chronic Toxoplasma infection 
may occur during pregnancy particularly in those who are severely immunocompromised. 
There are cases of cerebral toxoplasmosis reported in HIV-infected pregnant women and 
congenital toxoplasmosis in the fetus of these infected mothers but it is found only at a low 
incidence (Dunn et al, 1997). A case of CT was earlier reported in an HIV-infected pregnant 
woman who responded well with a standard regimen of pyrimethamine and sulfadiazine, 
with a normal fetal outcome (Hedriana et al, 1993). Another case of CT was confirmed in an 
HIV-infected pregnant woman during the puerperium with her CD4 count being < 200 
cells/cumm (Biedermann et al, 1995). A prophylactic treatment was recommended to 
prevent maternal reactivation and congenital transmission of toxoplasmosis in such a case. 
In recent years, an HIV-infected pregnant woman with CT who was at risk for transmitting 
HIV (low CD4 and high viral load) and Toxoplasma infections to her fetus; she responded 
well to anti-Toxoplasma therapy and HAART (Nogueira et al, 2002). In this case, the 
combined Toxoplasma therapy (pyrimethamine and sulfadiazine) and HAART were 
benefitial not only to the mother but also prevented transmission to the fetus. Despite this 
evidence of success in most cases, there have been reports of poor outcomes when an HIV-
infected mother has CT during pregnancy, with vertical transmission of one or both 
infections to the fetus and an increase of morbidity and mortality in the mother (Mitchell et 
al, 1990; O’Riordan & Farkas, 1998; Fernandes et al, 2009). Maternal-fetal transmission of 
toxoplasmosis due to reactivation of chronic infection during pregnancy occurs in mothers 
with a very low CD4 cell counts (Minkoff et al, 1997) or in the presence of other 
immunological disorders (Montoya & Liesenfeld, 2004). A case of severe congenital 
toxoplasmosis was reported from an HIV-infected mother with moderate 
immunosuppression as a result of reactivation (Bachmeyer et al, 2006). This indicates that a 
routine screening for not only children from HIV-infected mothers should be used to detect 
congenital toxoplasmosis but also in pregnant women to confirm an early diagnosis of a 
reactivation of a chronic Toxoplasma infection. The first case of congenital toxoplasmosis was 
reported in Brazil, this was from an HIV-infected mother with a high titer of IgG but 
negative for IgM antibodies (Cruz et al, 2007). This highlights the special attention needed 
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for analysis of maternal titers of anti-Toxoplasma antibody during HIV prenatal care. Two 
years later, a contrasting study reported a case of congenital toxoplasmosis in an HIV-
infected pregnant woman with a low titer of IgG to T. gondii and a negative result for IgM 
antibodies (Lago et al, 2009). It is important to keep this in mind that a high titer for IgG 
antibody is fairly common in HIV-infected mothers. This phenomenon is not significantly 
associated with an increased risk of congenitally acquired toxoplasmosis during pregnancy. 
Compliance to antiretroviral therapy is a medical challenge which led to a rare case of 
congenital toxoplasmosis from a severely immunosuppressed HIV-infected woman as a 
result of reactivation (Fernandes et al, 2009). Under this circumstance, prophylaxis is 
required in addition for strict adherence to therapy in pregnant women infected with HIV. 
The most recent cases of congenital toxoplasmosis were reported from HIV-infected 
mothers who had a high titer for IgG and were negative for IgM antibodies (Azevedo et al, 
2010). Due to the increasing number of HIV- infected women in childbearing age 
worldwide, the possibility of maternal-fetal transmission from mothers infected with 
chronic Toxoplasma infection is more likely to occur and may have a huge impact on public 
health perspectives, especially in those endemic areas with Toxoplasma infection. It is 
surprising that there has been no reported case of clinically confirmed congenital 
toxoplasmosis or CT in HIV-infected pregnant women from Asian countries. In fact, HIV 
infection is fast growing in this region compared to other parts of the world. This could be 
explained either because of the overall low prevalence of toxoplasmosis in HIV-infected 
women or those cases of toxoplasmosis are under-reporting. Therefore, clinicians should be 
more aware of this parasitic infection to establish an early diagnosis and better management 
in both qualities of care and treatment among HIV-infected pregnant women in this 
continent. To conclude, HIV and Toxoplasma infections are common in developing countries 
with resource limited settings, it is therefore imperative that drugs related to both infections 
are easily accessible particularly for pregnant women living in low-socio-economic 
conditions. Due to the effectiveness of anti-Toxoplasma therapy and increasing global 
availability of HAART in HIV-infected pregnant women, the incidence of congenital 
toxoplasmosis should decline or even disappear. 
4.2 Cerebral toxoplasmosis  
Neurological complications of AIDS patients are often due to opportunistic infections (OIs) 
in the central nervous system (CNS). Toxoplasmosis is one of the most common CNS-OIs 
and causes high rates of morbidity and mortality in patients with advanced HIV infection. 
With the advent of the HIV pandemic, epidemiological studies have shown CT to be one of 
the most common OIs in AIDS patients and the most commonly reported CNS-OIs on 5 
continents: Asia (India, Malaysia and Thailand), Europe (France, United Kingdom and 
Germany), North America (USA), South America (Brazil and Mexico), and recently from 
South Africa (Amogne et al, 2006; Oshinaike et al, 2010). The incidence of CT varies 
according to geographical locations and the prevalence of Toxoplasma infections in the 
general population. Other factors such as the mode of transmission, gender, ethnicity, severe 
immunodeficiency, and differences in genotypes of T. gondii isolates are also found to 
influence the occurrence of CT (Richards et al, 1995; Khan et al, 2005). In the pre-HAART 
era, ~25% of AIDS patients from France had CT compared to ~10% in some cities from the 
USA (Dal Pan & McArthur, 1996). The rate of CT was found to vary from  between 16-40% 
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in the USA and UK, ~60% in Spain, 50-80% in Brazil, 75-90% in France (Pereira-Chioccola et 
al, 2009), and <20% in Asian countries including India (Sharma et al, 2004), Malaysia 
(Nissapatorn et al, 2003-2007), or Thailand (Anekthananon et al, 2004; Subsai et al, 2004). CT 
is frequently diagnosed in adults but rarely occurs in children with AIDS; the infection 
accounted for 0.86% of AIDS-defining illnesses (Richards et al, 1995) or <1.0 per 100 person 
years (Dankner et al, 2001; Gupta et al, 2009). CT is the most common cause of focal 
intracerebral lesion(s) in patients with AIDS. More than 95% of CT is caused by the 
reactivation of latent (chronic) Toxoplasma infection as a result of the progressive loss of 
cellular immunity in AIDS patients (Luft & Remington, 1988). In clinical practice, the 
incidence of CT patients is related both to Toxoplasma IgG seropositivity and the CD4 cell 
count. The risk of developing CT among seropositive patients with AIDS was 27 times that 
of seronegative ones (Oksenhendler et al, 1994). AIDS patients who are Toxoplasma 
seropositive, have CD4 count of <100 cells/cumm, and failure to receive prophylaxis are 
among the identified risk of developing CT (Luft and Remington, 1992; Nascimento et al, 
2001; Nissapatorn et al, 2004). The clinical presentations of CT depend on the number of 
lesions and location. Headache, hemiparesis and seizure (Nissapatorn et al, 2004; Vidal et al, 
2005a) are among the most common neurological presentations found in CT patients. Other 
clinical manifestations include disarthria, movement disorders, memory and cognitive 
impairments and neuropsychiatric abnormalities. These neurological deficits remain in 
surviving patients even after good clinical response to therapy (Hoffmann et al, 2007). More 
than 50% of CT patients may have focal neurological findings. CT is a life-threatening but 
treatable condition provided there is early diagnosis and treatment. CT can be prevented by 
primary behavioral practices in avoiding acquisition of Toxoplasma infection such as 
consumption of well cooked meat, avoiding close contact with stray cats, contaminated soil 
and/or water, and receiving unscreened blood transfusions. Compliance to both therapeutic 
regimens for treatment and prophylaxis of toxoplasmosis is an imperative to prevent relapse 
of CT in areas where HAART is not fully accessible for people living with HIV/AIDS. This 
ultimately reduces the number of hospital admissions as well as the mounting medical care 
cost of AIDS-associated CT patients, particularly in limited resource settings. 
There are atypical/unusual clinical manifestations reported in AIDS-associated CT patients. 
Ventriculitis and obstructive hydrocephalus, characteristics of congenital toxoplasmosis, are 
rarely seen in adult AIDS-associated CT. Ventriculitis has so far been reported in nine adult 
AIDS patients (Cota et al, 2008), accompanied by hydrocephalus, occurred as the primary 
manifestations of toxoplasmosis or as complications of a preexisting, recognized cerebral 
toxoplasmosis. In addition, hydrocephalus without mass lesions was the only abnormal 
finding from a computed tomography (CAT) scan in an adult AIDS patient (Nolla-Salas et 
al, 1987). It is very rare for patients with CT to present as a neuropsychiatric illness with an 
acute psychosis followed by a rapid mental and somatic decline, however one case has been 
reported in a patient with AIDS (Ilniczky et al, 2006). Extrapyramidal movement disorders 
are one of the atypical clinical manifestations reported in AIDS patients. Toxoplasmosis is 
one of the main underlying opportunistic infections and causes movement disorders in 
AIDS patients. These movement disorders are becoming well known and increasingly 
recognized as a potential neurological complication in AIDS patients (Tse et al, 2004). In 
hyperkinetic movements, holmes (also known as rubral or midbrain tremor) tremor is the 
earliest reported symptom of CT and might present with other focal neurological signs that 
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indicates a midbrain localization (Koppel & Daws, 1980). The appearance of hemichorea-
hemiballism is considered as a pathognomonic of CT and is most commonly associated with 
a subthalamic abscess (Navia et al, 1986; Maggi et al, 1996). The presence of hemichorea-
hemiballism in CT patients is low (7.4% of cases) compared to the pathological studies 
which show 50% of Toxoplasma abscesses occur in the basal ganglia (Navia et al, 1986; Maggi 
et al, 1996). Generalized chorea may occur as a result of bilateral abscesses of toxoplasmosis 
(Gallo et al, 1996). Myoclonus, is generalized and elicited by sudden auditory stimuli that 
resembles a startled response, has also been described in AIDS-associated CT patients 
(Maher et al, 1997). A case of focal dystonia of the left arm and hand has been reported in an 
AIDS patient due to the right lenticular nucleus and thalamic abscesses of toxoplasmosis 
(Tolge & Factor, 1991). A few cases with parkinsonian features, hypokinetic movement 
disorders, due to toxoplasmosis were also described in patients with AIDS (Carrazana et al, 
1989; Murakami et al, 2000). Movement disorders in AIDS patients and particularly in 
countries with a high prevalence of toxoplasmosis, should indicate the possibility of CT 
(Noël et al, 1992). In AIDS patients, opportunistic infections may affect endocrine organs. 
Diabetes insipidus (DI) is uncommon but has also been reported in relation to CT. Imaging 
studies may demonstrate pathological situations and assist in the diagnosis (Brändle et al, 
1995). A case of CT with massive intracerebral hemorrhage leading to a fatal vehicular crash 
was also reported in a patient with AIDS (Gyori & Hyma, 1998). Cerebellar toxoplasmosis is 
another infrequent complication of HIV/AIDS that should prompt a high index of clinical 
suspicion and early institution for presumptive therapy in poor resource settings (Emeka et 
al, 2010). These unusual neurological presentations of AIDS patients associated 
toxoplasmosis have rarely been reported in Asia (Chaddha et al, 1999; Nissapatorn et al, 
2004; Subsai et al, 2006; Nissapatorn et al, 2007).  
4.3 Extracerebral toxoplasmosis 
Overall, the prevalence of extracerebral toxoplasmosis (ECT) in patients with AIDS is 
estimated to be 1.5%-2% (Rabaud et al, 1994) which is far less common than CNS 
toxoplasmosis. Ocular toxoplasmosis (OT) is the most common form of ECT associated with 
CT, being detected in 50% of ECT in AIDS patients and has the best prognosis (Rabaud et al, 
1994; Zajdenweber et al, 2005). OT, in contrast to intracranial disease, is uncommon in 
patients with AIDS (Lamichhane et al, 2010). However, OT is a serious eye problem in HIV-
infected patients, especially in developing countries (Chakraborty, 1999). OT is an important 
disorder and may be the first manifestation of life-threatening intracranial or disseminated 
T. gondii infections. Accurate diagnosis may allow early referral to a neurologist and 
infectious diseases specialist (Holland et al, 1988). Generally, OT tends to cause 
retinochoroidal scars with less retinal pigment epithelium hyperplasia (Arevalo et al, 1997). 
It has no association between the ocular findings and a positive titer of toxoplasmosis 
(Mansour, 1990.). However, the presence of IgM antibodies may support this diagnosis, 
although antibody levels in AIDS patients may not reflect the magnitude of the disease 
(Gagliuso et al, 1990). OT was first reported in 2 of 34 AIDS patients with a ‘cotton wool’ 
spot as one of the most common retinal manifestations (Schuman & Friedman, 1983). It is 
also characterized by several features, including single or multifocal retinal lesions in one or 
both eyes or massive areas of retinal necrosis. These lesions that are not associated with a 
pre-existing retinochoroidal scar indicate a manifestation of acquired rather than congenital 
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disease (Gagliuso et al, 1990). A unique pattern of bilateral retinitis due to OT was observed 
in a patient in the late stages of AIDS in which the recognition of this pattern is important 
for providing the appropriate treatment of an immunosuppressed patient (Berger et al, 
1993). Toxoplasmosis should therefore be considered in the differential diagnosis in an AIDS 
patient with necrotizing retinitis (Moorthy et al, 1993). There have been few studies reported 
on toxoplasmosis as being one of the most common causes of neuro-ophthalmological 
disorders in neurologically symptomatic HIV-infected patients such as palsy involving the 
sixth and third cranial nerves (Mwanza et al, 2004). Thus, clinicians should be more aware of 
this pathogen to avoid consequences, such as damaging visual pathways leading to visual 
impairment or blindness in these patients. With more affordable and accessibility of 
HAART, the prevalence of ocular toxoplasmosis will decline over time. 
Toxoplasmosis is known to cause widely disseminated and extracerebral disease which is 
less common and more difficult to diagnose in AIDS patients. Toxoplasma-induced cystitis or 
pseudoneoplastic bullous cystitis is rarely detected in these patients. The diagnosis may be 
difficult because this condition is associated with misleading radiologic and endoscopic 
findings (Welker et al, 1994). With these studies, the diagnosis was eventually confirmed by 
the presence of Toxoplasma cysts on histopathological examination of bladder biopsies 
(Hofman et al, 1993). Therefore, disseminated toxoplasmosis should be considered in the 
differential diagnosis of AIDS patients with culture-negative cystitis (Welker et al, 1994). For 
unclear reasons, gastrointestinal involvement is exceedingly rare and occurs only in the 
context of severe immunosuppression and disseminated disease (Merzianu et al, 2005). 
Gastric toxoplasmosis has been reported in AIDS patients. It presents as diarrheoa and other 
nonspecific GI symptoms. Biopsy shows the presence of Toxoplasma trophozoites in the 
forms of tachyzoites, bradyzoites, and pseudocysts which are mandatory for definite 
diagnosis. It responds well to anti-Toxoplasma therapy (Alpert et al, 1996; Merzianu et al, 
2005). It is of interest, that disseminated toxoplasmosis with sepsis has also been found in 
AIDS patients and should be considered in patients with sepsis of unknown origin (Artigas 
et al, 1994). ECT has also been diagnosed in the heart (Guerot et al, 1995; Chimenti et al, 
2007), lung (Touboul et al, 1986; Kovari et al, 2010), liver (Mastroianni et al, 1996), and spinal 
cord (Harris et al, 1990; Kung et al, 2011). ECT has a low incidence in AIDS patients. Many 
HIV-infected patients lack access to primary chemoprophylaxis and antiretroviral therapy, 
in limited resource settings hence, more cases are reported in this group.  
5. Neuropathology of toxoplasmosis: from pre to HAART era 
Toxoplasmosis is an important opportunistic infection, causing short-term and chronic 
mortality (Neuen-Jacob et al, 1993; Kumarasamy et al, 2010). Multifocal necrotizing 
encephalitis is the predominant neuropathological finding of CT in AIDS patients. 
Localization of multiple with ring enhancing lesions on neuroimaging in basal ganglia, 
frontoparietal cortex and thalamus suggests haematogenous spread. The predilection of T. 
gondii in the basal ganglia can result in a variety of movement disorders (Nath et al, 1993). 
The cerebral edema, encephalitic process and tissue destruction are significant and 
responsible for majority of neurological morbidity in HIV-infected patients presenting with 
focal brain lesion (Ammassari et al, 2000). Rupture of tissue cysts in AIDS- associated CT 
patients result in multiplication of bradyzoites into tachyzoites, which causes severe 
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inflammatory reaction. Three morphological patterns of brain lesions in patients with CT are 
produced based on the stage of infection and degree of tissue reaction (Shankar et al, 2005): 
(i) In the acute stage (less than a few weeks duration): appearance of a necrotizing abscess or 
encephalitis seen as poorly circumscribed necrotic foci with variable degrees of 
haemorrhage, perifocal edema, acute and chronic inflammation, macrophage infiltration, 
with numerous T. gondii tachyzoites and encysted bradyzoites along the periphery. Also 
common are vascular thrombosis/fibrinoid necrosis of vessel walls, with polymorph 
infiltration, hypertrophy and the presence of tachyzoites in the hypertrophie arterial wall. 
(ii) A chronic lesion (weeks to months) : organized abscesses are found in CT cases treated 
for  2 weeks and seen as well circumscribed foci of central necrosis with a rim of 
congestion. In contrast to the acute phase, the central foci of an acellular necrosis is 
surrounded by a granulomatous reaction, with macrophages containing tightly packed lipid 
and haemosiderin, prominent hypertrophic occlusive arteritis with dense lymphocytic 
cuffing, and only a few organisms. (iii) Patients treated for  1 month show chronic 
abscesses in CT appear as small cystic cavities or linear orange-yellow scars and 
macrophages containing lipid and haemosiderin surrounded by a dense gliotic reaction. 
Calcification of vessels occurs and organisms are rarely found. In addition, a CAT scan can 
present as a diffuse, non-necrotizing, rapidly progressive encephalitis. The histological 
appearance seen as nodules of micrioglial cells with encysted bradyzoites and dispersed 
tachyzoites within the nodules.  
Autopsy findings confirm the presence of the parasite and demonstration of Toxoplasma 
cysts is diagnostic of disseminated toxoplasmosis in AIDS patients (Holch et al, 1993). 
Despite the effectiveness of HAART, involvement of the brain in patients with AIDS 
remains a frequent autopsy finding (Masliah et al, 2000). AIDS-associated CT continues to 
be the major cause of mortality in the era of HAART (Rajagopalan et al, 2009; Kumarasamy 
et al, 2010). The expansion of earlier access to HAART could substantially reduce mortality, 
particularly in limited resource settings (Mzileni et al, 2008; Rajagopalan et al, 2009).  
The seroprevalence of toxoplasmosis is generally high in HIV-infected patients and 
approximately 10% of CT is reported in AIDS patients. There has been no report of such 
neuropathological findings related to toxoplasmosis found in AIDS patients from Malaysia 
and its neighboring countries in the Southeast Asian region such as Thailand. This may be 
due to the fact it is not a common practice to conduct an autopsy in HIV/AIDS patients that 
could give the actual prevalence of AIDS-associated CT being underestimated. CT is one of 
the most common opportunistic infections of the CNS (Wadia et al, 2001; Nobre et al, 2003) 
as reported in an autopsy series conducted in India (Lanjewar et al, 1998a; Lanjewar et al, 
1998b) and in other clinical settings (Petito et al, 1986; Souza et al, 2008). The majority of 
AIDS-related diseases diagnosed at autopsy had not been clinically diagnosed or suspected 
antemortem (Eza et al, 2006). The importance of an autopsy in evaluating clinical 
management and diagnosis (Eza et al, 2006) should be periodically done; particular in areas 
of high endemic toxoplasmosis where antiretroviral drugs, such as HAART, cannot be fully 
accessed. 
There is scanty data about AIDS-associated neuropathological findings during the HAART 
era in Asia and Sub-Sahara Africa. This is mainly due to delayed introduction of these 
agents to these regions. It is expected that more autopsy studies will be carried out in this 
part of the world in the near future. The incidence of toxoplasmosis in autopsy studies has 
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declined since the introduction of HAART in various countries, such as the USA (Langford 
et al, 2003) and France (Vallat-Decouvelaere et al, 2003). These studies show that autopsy 
findings can be a valuable means for determining the range and relative frequency of 
infectious diseases in these patients (Lucas et al, 1993). In addition, this can potentially have 
an immediate impact on patient care by enabling appropriate interventions, based on the 
results obtained (Lucas et al, 1993).  
6. Diagnostic approaches - from conventional to advanced technology 
Among patients with AIDS, cerebral involvement is more common and more serious than 
extracerebral toxoplasmosis. The definitive diagnosis is crucial for CT patients by directly 
demonstrating the presence of the tachyzoite form of T. gondii in the cerebral tissues. The 
presumptive diagnosis for CT, including the clinical presentations, radio-imaging findings, 
molecular and sero-diagnosis for Toxoplasma infection, and good response to anti-Toxoplasma 
therapy are widely accepted in clinical practice. The favorable outcome of CT is the 
improvement of clinical and radiological features after 2 to 3 weeks of initiated empirical 
therapy. The clinical diagnosis is a dilemma due to CT mimics with other brain diseases 
making it difficult to diagnose. Differential diagnosis of AIDS-associated CT is extremely 
important and the local neuroepidemiology and the degree of immunosuppression in the 
host are two key factors involved (Vidal et al, 2008). Primary CNS lymphoma is the main 
differential diagnosis of CT reported from developed countries (Manzardo et al, 2005). 
While, focal forms of cerebral tuberculosis (tuberculoma and, less likely tuberculous brain 
abscess) allow for differential diagnosis of CT mainly in developing countries (Trujillo et al, 
2005). Primary CNS lymphoma usually presents with a CD4 count of less than 50 
cells/cumm, CT occurs below 100 cells/cumm, and cerebral TB is more frequently present 
with a CD4 count above 200 cells/cumm (Vidal et al, 2004a; Vidal et al, 2005a; Vidal et al, 
2005b). In addition to these more common neurological diseases, the differential diagnosis 
of CT includes other opportunistic infections such as progressive multifocal 
leucoencephalopathy, herpes simplex encephalitis, and cryptococcal meningitis; AIDS-and 
non-AIDS-associated tumors such as metastases of disseminated lymphoma and 
glioblastoma multiforme, respectively; and vascular diseases. Overall, a rapid and accurate 
diagnosis of CT is necessary, as the earlier the treatment the better the clinical outcome and 
survival rate of these patients.   
6.1 Radiological diagnosis 
Radio-imaging findings, either by computed tomography (CAT scan) or magnetic resonance 
imaging (MRI), are useful tools for the presumptive or empirical diagnosis of CT. CT 
usually causes unifocal, and more frequently multifocal lesions, and less likely diffuse 
encephalitis. These findings are however not pathognomonic of CT. Radiological diagnosis 
(Vidal et al, 2005a) can be classified as typical findings of hypodense lesions with ring-
enhancing and perilesional edema, are observed in ~80% of CT cases. A typical pattern of 
hypodense lesions found without contrast enhancing and with an expansive effect, CT 
patients without focal lesions and MRI demonstrating focal lesions, and diffuse cerebral 
encephalitis without visible focal lesions, are shown in ~20% of these cases. An unusual but 
highly suggestive image of patients with CT is the ‘eccentric target sign’, which is a small 
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asymmetric nodule along the wall of the enhancing ring (Pereira-Chioccola et al, 2009). 
Figure 2 shows the main radiological features of AIDS-associated CT patients. A CAT scan 
seems to be a sensitive diagnostic method for patients with focal neurological deficits; 
however it may underestimate the minimal inflammatory responses seen during early 
disease (Gill et al, 1986). 
 
 
Fig. 4. Computed tomography images showing the spectrum of radiological findings of 
cerebral toxoplasmosis in HIV-infected patients. 
Hypodense lesion with ring-enhancing and perilesional edema (A); nodular enhancing 
and perilesional edema (B); without contrast enhancing and with expansive effect (C). A 
CAT scan with contrast enhancement showed no abnormalities (D1) and corresponding 
T2-weighted MRI showed multiple basal ganglia focal lesions, with high-intensity signals 
(D2). T1-weighted MRI showed a ring-enhancing lesion with a small, enhancing 
asymmetric nodule along the wall of the lesion (E) (‘the eccentric target sign’). The arrows 
show the abnormalities. (Courtesy of Dr.  Pereira-Chioccola VL and Dr. Vidal JE, São 
Paulo, Brazil.) 
MRI is recommended to be performed in patients with; neurological symptoms and positive 
serology to anti-Toxoplasma antibodies whose CAT scans show no or only a single 
abnormality, or persistent or worsening focal neurological deficits of disease if results of the 
initial procedure were negative (Luft & Remington, 1992). A CAT scan or MRI is useful for 
assessment of patients who had responded to initial empirical treatment. There may be a 
worsening of radiographic appearance in patients with a clinically improved condition 
before 3 weeks, and complete resolution of cerebral lesions seen on a CAT scan may vary 
from 3 week to 6 months after initiation of therapy (Luft & Remington, 1992). An evidence 
of either clinical or radiographic improvement within 3 weeks of initial therapy provides a 
confirmed diagnosis of patients with CT. 
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6.2 Serological diagnosis 
Cerebral toxoplasmosis poses a diagnostic problem that relies on classical serological 
methods to detect anti-Toxoplasma immunoglobulins because clinical blood samples from 
patients with immunodeficiency can fail to produce sufficient titers of specific antibodies. 
Sero-evidence of Toxoplasma infection, independent of antibody levels, is generally seen in 
all patients before developing CT (Carme et al, 1988). Most CT patients have high titers of 
anti-Toxoplasma IgG antibodies with high IgG avidity that provides serological evidence of 
infection (Raffi et al, 1997; Vidal et al, 2005a), and this also supports a conclusion that this is 
the result of a secondary reaction of latent or chronic Toxoplasma infection (Dardé, 1996). 
Therefore, it is important to determine the Toxoplasma serostatus in all HIV-infected patients 
in order to define the population at risk for CT. At the onset of CT, significant rises in anti-
Toxoplasma antibody titers are found in only a minority of these patients (Carme et al, 1988). 
The level of rising titers may occur before the onset of CT and it does not seem to predict the 
occurrence of CT. Anti-Toxoplasma IgM antibody, as measured by the indirect fluorescent or 
ELISA tests, is rarely found in CT patients (Luft & Remington, 1992). In cases of CT, a 
negative or low titer of serological results or even the absence of anti-Toxoplasma antibodies 
does not exclude positive diagnosis and the initiation of anti-Toxoplasma therapy should be 
immediately started without delay if clinical and radiological presentations are consistent 
with CT (Luft & Remington, 1992; Nissapatorn et al, 2004). A positive serology result seems 
to be even less useful in areas where there is a high prevalence of toxoplasmosis in the 
general population (Pereira-Chioccola et al, 2009). While, a negative result does have a high 
negative predictive value (Vidal et al, 2008) Determination of an increase of intrathecal anti-
Toxoplasma IgG antibody production is normally characterized by the presence of T. gondii 
oligoclonal bands (OCBs) of IgG antibody in CT patients (Potasman et al, 1988). 
Immunological diagnosis using other clinical samples such as cerebrospinal fluid (CSF) is of 
limited use because of the sensitivity and specificity being only about 60-70% (Collazos, 
2003). T. gondii excretory/secretory antigens (ESAs) are an excellent serological marker for 
the diagnosis of CT in AIDS patients (Pereira-Chioccola et al, 2009). ESAs are produced by T. 
gondii tachyzoites, the form responsible for disease dissemination, which plays an important 
role in stimulating humoral and cellular immunities in order to control Toxoplasma infection 
(Carruthers & Sibley, 1997; Cérède et al, 2005). Anti-ESA IgG antibodies are also present in 
CSF sample of AIDS patients with CT which can be determined by ESA-ELISA and 
immunoblot techniques and these samples are clearly distinguishable from AIDS patients 
who are Toxoplasma seropositive but with other brain diseases (Pereira-Chioccola et al, 2009). 
6.3 Molecular diagnosis 
Since the serological status is solely useful to recognize whether the patient is at risk for 
reactivation, the direct detection of T. gondii DNA in biological specimens by polymerase 
chain reaction (PCR) has provided a major breakthrough for the diagnosis of toxoplasmosis 
(Reischl et al, 2003). Over a period of two decades, these molecular methods based on PCR 
and specific genetic markers have been developed for routine use in assisting serology for 
the diagnosis of CT patients. PCR techniques are suitable for patients with AIDS because 
these methods do not depend on the host immune responses and allow for direct detection 
of T. gondii DNA from a variety of clinical samples. In addition, these methods are rapid, 
sensitive, specific, less time consuming, and can be used to replace invasive procedures such 
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as stereotactic brain biopsy. The sensitivity and specificity of the PCR reactions depends on 
the types of reagents, protocols for DNA extraction, storage of clinical samples, and the 
timing between the start of a specific therapy and collection of clinical samples, which can 
make the interpretation of results difficult (Pereira-Chioccola et al, 2009). Among 
clinical/biological samples, blood and CSF are the most frequently used for the detection of 
T. gondii DNA in patients with CT. To yield a better result, clinical samples should be 
collected before or up until the first 3 days of anti-Toxoplasma therapy because the diagnostic 
sensitivity will be reduced after the first week of this specific treatment (Vidal et al, 2004b). 
In CSF samples, the varying sensitivity of the PCR technique ranges from 11.5% to 100% but 
a high specificity (96-100%) has been reported using CSF specimens (Novati et al, 1994; 
Dupon et al, 1995; Vidal et al, 2004b). The collection of CSF sample is invasive and is not 
recommended for patients with multiple brain lesions (Pereira-Chioccola et al, 2009). PCR in 
blood samples, as an alternative approach, has been reported with a wide range of 
sensitivities of between 16% and 86% (Dupouy-Camet et al, 1993; Dupon et al, 1995). A 
quantitative real-time PCR (qrtPCR), is a recent development among molecular methods, 
and accelerates the detection of T. gondii DNA in most positive samples and allows for 
amplification and simultaneous detection of DNA in 1 hour (Hierl et al, 2004). Its 
advantages over conventional and nested PCR include rapid, improved sensitivity, a broad 
dynamic range of targets, DNA quantitation and reduction of contamination. Despite these 
advantages, in some patients with low parasite load particularly in CSF samples; there is 
still the need for comparative results of both conventional nested and real-time quantitative 
PCR methods (Bretagne, 2003; Hierl et al, 2004; Apfalter et al, 2005). Future prospect on the 
diagnosis of patients with CT is more likely to rely on the development of molecular 
methods based on qrtPCR which provides quantitative results and is less time-consuming in 
preparation. However, this technique needs to have improved specificity and more 
importantly a reduction of the high cost of the necessary equipment. 
6.4 Other diagnostic methods 
There is a need for more specific or invasive approaches that will assist confirmation of the 
diagnosis of CT. Brain biopsy is generally reserved for those patients who present with a 
diagnostic dilemma or do not fulfill the criteria for presumptive treatment and for those 
patients who fail to improve clinically or radiologically over the succeeding 10-14 days after 
being empirically treated for toxoplasmosis initially so they do warrant a stereotactic brain 
biopsy (SBB) in order to institute specific and appropriate therapy (Luft & Remington, 1992). 
For patients with expansive brain lesions who fail to respond  to empirical treatment initiated 
for CT within 14 days, SBB should be seriously considered relatively early in the course of 
treatment, with or without change in therapy (Pereira-Chioccola et al, 2009). Surprisingly, SBB 
is not commonly used for the diagnosis of CT or CT-associated other opportunistic CNS 
diseases in Asian countries (Yeo et al, 2000) compared to other settings where CT cases have 
been reported in patients with AIDS. Brain biopsies do not influence survival of CT patients 
(Sadler et al, 1998). SBB is an efficient, safe and important diagnostic procedure. In selected 
patients even expensive investigations should be undertaken before considering specific 
therapy and cost effective homecare (Armbruster et al, 1998). This procedure should be 
performed early during the patient's evolution in order to achieve a prompt and accurate 
diagnosis and to guide the therapeutic scheme for AIDS patients with FBL (Corti et al, 2008). 
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Recently, genotyping analysis of T. gondii strains isolated from clinical samples has been 
conducted in HIV-infected patients from different settings. However, it remains doubtful on 
how to ascertain the association between T. gondii strains and human toxoplasmosis since 
the majority of infected individuals are chronic and without any clinical symptoms, and it is 
difficult to isolate T. gondii strains from these patients. Therefore, a larger sample size should 
be carried out in human patients to identify specific T. gondii strains using high resolution 
typing methods such as multiplex nested PCR-RFLP which can genotype some DNA 
samples extracted directly from infected tissues. Serotyping of T. gondii strains has proved to 
be a promising tool using serum samples to overcome the diagnostic challenge (Kong et al, 
2003; Peyron et al, 2006; Morisset et al, 2008; Sousa et al, 2008; Sousa et al, 2009). However, 
due to the limitation of serotyping it is not possible to differentiate type II from non-type II 
strains particularly in South America where there is a high diversity of T. gondii strain types. 
At present, this requires further developments of typing analyses to facilitate and be 
incorporated into the routine diagnosis of patients with CT.   
7. Therapeutic approaches: from specific treatment to HAART  
7.1 Anti-Toxoplasma therapy 
One of the keys after diagnoses is how patients respond to the different therapeutic 
regimens used for treating this opportunistic disease. Most patients with CT respond well to 
anti-Toxoplasma agents as demonstrated by findings from studies in various settings. 
However, about 10% of CT cases died despite what was thought to be adequate treatment 
(Vidal et al, 2005a ). There are few options other than anti-Toxoplasma regimens used as first-
choice initial therapy; 6 weeks with sufadiazine (1.0-1.5 g per oral [PO] every 6 h) with 
pyrimethamine (100-200 mg PO loading dose, then 50 mg PO daily) and folinic acid (10-20 
mg PO daily) that can reduce the hemato-toxicities related to pyrimethamine (Portegies et 
al, 2004). This standard combination has been successfully used in treating CT but has been 
associated with high toxicities such as Lyell’s syndrome or Steven-Johnson syndrome 
(Katlama et al, 1996a; Torre et al, 1998). The other regimen is trimethoprim/sulfamethoxazole 
(Co-trimoxazole, 5/25 mg/kg PO or intravenous (IV) every 12 h for 4-6 weeks) (Canessa et 
al, 1992). This therapeutic regimen has been confirmed for its efficacy and safety in a single 
available randomized clinical trial (Canessa et al, 1992; Torre et al, 1998; Dedicoat & 
Livesley, 2006; Béraud et al, 2009). Several alternative therapies, principally used in patients 
who are intolerant to this combination, have been reported to be effective, including 
clindamycin and pyrimethamine or sulfadiazine (Katlama et al, 1996a; Tsai et al, 2002), 
clarithromycin and pyrimethamine (Fernandez-Martin et al, 1991), clindamycin and 5-
fluoro-uracil (Dhiver et al, 1993), azithromycin and pyrimethamine (Saba et al, 1993; 
Jacobson et al, 2001), clindamycin and fansidar (Nissapatorn et al, 2004), sulfadoxine and 
pyrimethamine (Amogne et al, 2006), and atovaquone (Torres et al, 1997). There was no 
superior regimen among the three following combinations: pyrimethamine plus 
sulfadiazine, pyrimethamine plus clindamycin (Katlama et al, 1996a), and pyrimethamine 
plus sulfadiazine with Co-trimoxazole (Torre et al, 1998) that were reported in a recent 
review of comparative studies (Dedicoat & Livesley, 2006).  
There is one case of toxoplasmosis resistant to standard combination therapy (pyrimethamine 
and sulfadiazine) that was improved with clindamycin and pyrimethamine (Huber et al, 
1995). The other case was an AIDS patient with toxoplasmic myelopathy and myopathy 
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resistant to standard anti-Toxoplasma therapy due to the possibility of immune reconstitution 
of the inflammatory syndrome, was reported (Kung et al, 2011). Another study suggested 
atovaquone as being effective in AIDS cases with resistant toxoplasmosis (Lafeuillade et al, 
1993). This helps to identify drugs that are effective and may act synergistically (McFadden et 
al, 2001). Relapses of CT are frequently observed in AIDS patients non-compliant to therapy or 
prophylaxis, and in those who develop adverse drug effects (Luft & Remington, 1992; 
Nissapatorn et al, 2004; Béraud et al, 2009). There has been no evidence of treatment-induced 
resistance so far reported that have contributing to a relapse of CT. Few studies have arrived at 
a solution of how to prevent relapses. Pyrimethamine and sulfadoxine twice a week appears to 
give promising results for prevention of CT. Allergic reactions are usually mild and disappear 
on continuation, but may limit the value of this regimen (Ruf et al, 1993). Daily doses of 
pyrimethamine and sulfadiazine are more effective as maintenance therapy for preventing 
relapses of CT (4.4 compared to 19.5 per 100 patient-years; incidence rate ration, 4.36; p=0.024) 
than twice weekly administration (Podzamczer et al, 1995). Pyrimethamine and clindamycin 
has been shown to be a valuable alternative for treatment but is less effective, particularly for 
the long term prevention of relapses (Katlama et al, 1996a). Azithromycin and pyrimethamine 
have been used as alternative therapy, but maintenance with this combination or oral 
azithromycin alone is associated with relapses (Jacobson et al, 2001).  
Atovaquone is a unique naphthoquinone with broad-spectrum antiprotozoal activity. It has 
been found to be effective against tachyzoites in vitro and may kill bradyzoites within cysts 
at a higher concentration. Atovaquone is frequently used in combination with other agents 
in treating CT. Experimental studies have shown that the efficacy of atovaquone was 
enhanced when other agents were added, such as pyrimethamine, sulfadiazine, 
clindamycin, or clarithromycin (Guelar et al, 1994). An intravenous preparation is highly 
effective in murine models with reactivated toxoplasmosis (Schöler et al, 2001; Dunay et al, 
2004). In AIDS patients, the only study to report failure with atovaquone during treatment 
found that a high temperature may induce inactivation of the product in the absence of food 
intake (Duran et al, 1995). Atovaquone has consistently been found to be a promising 
therapeutic for salvage therapy in CT patients who were intolerant to or who failed 
standard regimens (Guelar et al, 1994; Katlama et al, 1996a; Torres et al, 1997; Chirgwin et al, 
2002). However, the role of atovaquone in the treatment and prophylaxis of CT in AIDS 
patients is not well defined and more studies are required before a firm recommendation 
can be made (Baggish & Hill, 2002). The treatment of choice is often directed by the available 
therapy, particularly in resource-poor settings. An important question is whether the 
incidence of secondary reactivation or relapse cases of CT may begin to rise in the future. 
This depends on how the efficacy of the current treatment regimens and new novel drugs, 
especially those that can destroy cyst/bradyzoite forms of the Toxoplasma parasite. Another 
important factor is increasing resistance to antiretroviral drugs in HIV-positive patients and 
the subsequent decline in CD4 cell counts (Kuritzkes et al, 2000) which has been reported in 
the recent years.  
7.2 Primary and secondary chemoprophylaxis 
Toxoplasmosis is one of the leading CNS-OIs, that causes morbidity and mortality in 
advanced stages of HIV-infected patients. Effective primary and secondary prophylaxis has 
been formulated to prevent the occurrence of CT (Katlama et al, 1996a; Bucher et al, 1997). 
Before the era of HAART, co-trimoxazole played an important role as a primary 
prophylactic agent in preventing the reactivation of toxoplasmosis in HIV-positive patients 
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(van Oosterhout et al, 2005). CT was still reported in HIV-infected patients with or without 
prophylaxis (Nissapatorn et al, 2004; Nissapatorn et al, 2007). To be consistent with previous 
reports and present situations in most resource limited settings, a current guideline 
recommends the use of a daily dose of a double-strength tablet of co-trimoxazole in 
Toxoplasma-seropositive patients who have a CD4 cell count below100 cells/cumm (CDC, 
2009). For AIDS patients who survive their first episode of CT, the risk of relapse is between 
30% and 50% if lifelong suppressive therapy is not provided (Leport et al, 1988; de Gans et 
al, 1992). Discontinuation of maintenance therapy (secondary/ suppressive therapy) for 
established CT patients is not recommended (USPHS/IDSA Prevention of opportunistic 
infections working group, 1997). In the pre HAART era, relapse rates of CT after 
discontinuation of maintenance therapy was approximately 50% (Katlama et al, 1996b). 
There are few regimens that have been used for secondary prophylaxis for CT patients; the 
combination of pyrimethamine (25-50 mg/day) plus sulfadiazine (500 mg every 6 h) plus 
leucovorin (10-20 mg/day) is a highly effective treatment. The use of this combined thrice-
weekly regimen (Podzamczer et al, 1995) or the same doses of sulfadiazine twice a day 
(Jordan et al, 2004) is an alternative option among non-compliance patients. The 
recommendation is for pyrimethamine plus clindamycin (600 mg clinidamycin every 8 h) 
for patients who are intolerant to sulfa drugs (CDC, 2009). Co-trimoxazole (960 mg twice 
daily) is another potential drug used in secondary prophylaxis for patients with CT (Duval 
et al, 2004). This agent (2.5/12.5 mg/kg PO every 12 h) is considered as safe, cheap and 
effective and can be an alternative choice (Pereira-Chioccola et al, 2009) to increase drug 
adherence in areas where other maintenance therapies are not available.  
7.3 Highly active anti-retroviral therapy (HAART)  
For more than two decades now, the use of HAART in HIV-infected patients has resulted in 
an improved quality of life and an increase in the length of time that patients remain free 
from opportunistic infections (Mocroft et al, 1998; Palella et al, 1998). A higher CNS 
Penetration-Effectiveness (CPE) score of antiretroviral drugs is increasing the survival rate 
of CT patients (Lanoy et al, 2011). In CT cases, there is no recommendation for the timing of 
HAART when CT is present in antiretroviral-naïve patients. However, HAART should be 
started at least 2 weeks after an anti-Toxoplasma regimen was initiated in these patients 
(Manzardo et al, 2005; Pereira-Chioccola et al, 2009). In HIV-infected patients receiving 
HAART, primary prophylaxis for CT can be safely discontinued in patients whose CD4 cell 
counts increase to >200 cells/mm3 (CDC, 2009). It is a medical challenge to decide whether 
secondary prophylaxis should be continued while HIV-infected patients are receiving 
HAART. If maintenance therapy is stopped, recurrence of toxoplasmosis may allow for 
permanent damage to cerebral and visual functions which is potentially harmful to an 
affected person (Stout et al, 2002). While maintenance therapy is still essential, evaluation of 
T. gondii-specific immune responses might be the other important step for improving 
estimates of the individual risk of CT and CT relapse (Hoffmann et al, 2007). Otherwise, 
secondary prophylaxis can be safely discontinued in CT patients receiving HAART with 
CD4 cell count of > 200 cells/cumm after 6 months (Pereira-Chioccola et al, 2009). This same 
prophylaxis should be reintroduced in patients with CD4 cell count of < 200 cells/cumm 
(CDC, 2009). While, primary and secondary prophylaxis against CT can also be safely 
discontinued after the CD4 cell count has increased to  200 cells/cumm for more than 3 
months in HIV-infected patients receiving HAART (Miro et al, 2006). These strategies can 
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help in reducing the toxicity, pill overload, and expense associated with complicated 
therapeutic regimens. Considering that CT patients have a high chance of early death, 
HAART should be immediately initiated after CT diagnosis and prophylaxis should be 
maintained in these patients who fail to respond to antiretroviral therapy. 
8. Immune Reconstitution Inflammatory Syndrome (IRIS) - from past to future 
concerns 
Anti-retroviral therapy partially restores the immune function of HIV-infected patients, 
thereby remarkably reducing morbidity and mortality of opportunistic infections in general 
and CT in particular. The incidence of opportunistic infections, including CT and ECT has 
decreased, particularly in areas where antiretroviral therapy, including HAART, is 
accessible (Kaplan et al, 2000; Subsai et al, 2006; Lian et al, 2007). HAART has reduced 
relapse in cases of toxoplasmosis and has improved survival in these HIV-infected patients. 
This may be due to the successful suppression of virus replications followed by an increase 
in CD4+ lymphocytes, a partial recovery of T-cell specific immune responses and decreased 
susceptibility to both local and systemic opportunistic pathogens (Silva & Araújo, 2005). 
HIV-associated IRIS is the clinical worsening of opportunistic infections that result from 
enhancement of pathogen-specific immune responses among patients responding to 
antiretroviral treatment (Lawn & Wilkinson, 2006). IRIS has been widely recognized in CT 
patients following initiation of HAART and development of a paradoxical clinical 
deterioration despite an increased CD4 cell count and decreased HIV viral load which leads 
to the rapid restoration of the immune system (Gray et al, 2005). So far, more than 20 cases 
of IRIS-associated CT have been reported in the literature (Table 2). A low CD4 cell count 
has been identified as a significant risk factor in AIDS patients with CT (Tsambiras et al, 
2001; de Boer et al, 2003; Sendi et al, 2006; Chen et al, 2009; Caby et al, 2010; Kung et al, 2011) 
due to impaired proliferative response to Toxoplasma antigen (Belanger et al, 1999), a 
decreased production of interferon  (Ullum et al, 1997), and it is found to be more common 
that IRIS develops in HIV-infected patients (Jevtović et al, 2005). Therefore, monitoring of 
CD4/CD8 T cells in patients on HAART might serve as a better marker for the restoration of 
T. gondii-specific immune responses than the total number of CD4 cells count (Furco et al, 
2008). Immune reconstitution under HAART has been associated with a restoration of 
immune responses against T. gondii (Fournier et al, 2001). In the case where IRIS is suspected 
in CT patient, close observation for 7-15 days, a higher steroid dose to control IRIS 
(Venkataramana et al, 2006), uninterrupted HAART, and continued treatment for 
toxoplasmosis can resolve this problem without biopsy (Tremont-Lukats et al, 2009). Based 
on reported cases of CT-associated IRIS from different studies, this could verify its 
association that it can develop in a substantial numbers of HIV-infected patients receiving 
HAART. No case of IRIS-related toxoplasmosis has ever been reported among AIDS 
patients in Malaysia even though CT was one of the most common systemic opportunistic 
infections in AIDS patients (Nissapatorn et al, 2004; Lian et al, 2007). Toxoplasmosis is a 
common neurological opportunistic infection in industrialized countries for which HAART 
is often initiated fairly early compared to developing or resource-limited settings. As for the 
increasing use of HAART worldwide, the care for patients receiving HAART will need to 
incorporate monitoring for and treating complications of IRIS (Agmon-Levin et al, 2008), 
including impaired CD4-cell immune reconstitution upon HIV therapy in patients with CT 
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Rodríguez-Rosado et al, 
1998 
Spain 3 Cerebral 
toxoplasmosis 
-  
González-Castillo et al, 
2001 
Spain 1 Cerebral 
toxoplasmosis 
456 
Tsambiras et al, 2001 USA 1 Cerebral 
toxoplasmosis 
83 
de Boer et al, 2003 The Netherlands 1 Cerebral 
toxoplasmosis 
43 





Sendi et al, 2006 Switzerland 1 Immune recovery 




Subsai et al, 2006 Thailand 2 Cerebral 
toxoplasmosis 
-  
Huruy et al, 2008 Ethiopia 2 Cerebral 
toxoplasmosis 
- 
Chen et al, 2009 USA 1 Cerebral 
toxoplasmosis 
29 
Klotz et al, 2009 Ethiopia 7 Cerebral 
toxoplasmosis 
50-100 
McCombe et al, 2009 Canada 1 Cerebral 
toxoplasmosis 
2 
Tremont-Lukats et al, 
2009 
USA 1 Cerebral 
toxoplasmosis 
14 
Cabral et al, 2010 Brazil 1 Cerebral 
toxoplasmosis 
276 
Caby et al, 2010 France 1 Placental IRIS 7 (pregnancy)  
Martin-Blondel et al, 
2010 
France 3 Cerebral 
toxoplasmosis 
9, 25, 23 










Table 2. Summary on reported cases of immune reconstitution inflammatory syndrome 
(IRIS) associated toxoplasmosis in HIV-infected patients. 
(Kastenbauer et al, 2009). As the number of AIDS-associated CT cases treated with HAART 
increases, the complications of IRIS-CT may become more common and easily recognizable, 
particularly in areas where toxoplasmosis is endemic. Therefore, increased awareness of 
IRIS is importance to clinicians along with early diagnosis and appropriate treatment in 
managing AIDS patients. 
www.intechopen.com




Despite a decline in both morbidity and mortality in HIV-infected patients in developed 
countries including the United States and Europe, toxoplasmosis remains an important 
disease and is unlikely to be eradicated. Toxoplasmosis still occurs in those not diagnosed 
with HIV and not receiving medical care, those not receiving prophylaxis, and those not 
taking or not responding to HAART. There are very few reports regarding resistance to the 
drugs used for toxoplasmosis. Resistance in HIV cases and the action of anti-retroviral 
therapy with or without IRIS may contribute to an increase in the incidence of CT. In 
developing countries where anti-retroviral therapy is still lacking, HIV-infected patients are 
at high risk for CT, these regions include China, India, South America, Southeast Asia and 
most importantly sub-Saharan Africa. A better understanding of the clinico-epidemiology of 
toxoplasmosis, and improved efforts in prevention, diagnosis and treatment, are needed. 
The role of infections with this parasite requires further study, including as to whether 
infections, such as CT have an impact on HIV/AIDS patients. 
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